Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial.

No Thumbnail Available
Authors
Corrie, P G [et al]
Goodman, Andrew
Journal
Annals of oncology : official journal of the European Society for Medical Oncology
Type
Journal Article
Publisher
Oxford Journals
Rights
Archived with thanks to Annals of oncology : official journal of the European Society for Medical Oncology
Bevacizumab is a recombinant humanised monoclonal antibody to vascular endothelial growth factor (VEGF) shown to improve survival in advanced solid cancers. We evaluated the role of adjuvant bevacizumab in melanoma patients at high risk of recurrence.
Citation
Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial. 2018 Ann. Oncol.
Note